Microsure, a leading Dutch developer of micro-surgical robotics, closed a financing round of € 2.7 million, as an extension of the 2020 Series B round. The funds will be used to continue the initial clinical roll-out of MUSA, the company’s CE-marked and approved micro-surgical robot assistant. This round was led by Invest-NL, the other 50% of the funding came from the existing shareholders BOM Brabant Ventures and venture capital investor Innovation Industries, as well as from private investor Ten Cate Investeringsmaatschappij (TCIM).
MUSA is the world’s first clinically available CE-certified surgical robot assistant for microsurgeons. The device has been developed by a team of engineers and surgeons, creating a solution that’s compatible with current operating techniques, instruments, and other operating room equipment. MUSA seamlessly scales down motion and filters out tremors to keep a steady hand at any time throughout every microsurgical procedure. This can improve clinical outcomes for various micro-surgical indications such as lymphatic-venous anastomosis, distal nerve repair, vascularized tissue transplantation, and other complex microsurgical procedures.
The initial planned clinical roll-out of MUSA was seriously delayed due to the Covid-19 pandemic, giving the company the opportunity to also further develop a number of improvements to the current MUSA system, which will be available on the market in the course of 2022.
Sjaak Deckers appointed as the new CEO
Microsure appointed Sjaak Deckers as its new CEO, to lead the company into its next phase of market entry. Deckers is an experienced MedTech executive with broad product development experience, as CEO of two earlier MedTech startup companies, GTX Medical and Sapiens (Steering Brain Stimulation), and as a venture partner at European Healthtech Builder NLC. He also held senior management positions at Medtronic, Philips Healthcare, and Philips Research.
Deckers expects the new funding to enable Microsure to further advance MUSA: “Despite the Covid-19 restrictions, our engineers have made tremendous improvements to the current MUSA system, and our clinical team gained further adoption experience of microsurgery in the Netherlands with the MUSA system. This investment will help us expedite our further clinical validation.”